Cipla receives USFDA nod to market Lanreotide injection in American market

The company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (USFDA). The FDA approval is based on new drug application (NDA), it added. Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors, in the American market. The company said it has received final approval for Lanreotide Injection from the US Food and Drug Administration (USFDA). Pharma cipla usfda new drug application health news Biopharmaceuticals American pharmaceutical market The FDA approval is based on new drug application (NDA), it added. The Lanreotide injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cipla MD and Global CEO Umang Vohra said, "This approval is a significant step for our US business and is in line with our aspiration to continue growth in our complex product pipeline and address unmet patient needs." The company's product is generic equivalent of Ipsen Biopharmaceuticals Inc's Somatuline Depot. According to IQVIA, Somatuline Depot had US sales of around USD 867 million for the 12-month period ended October 2021.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!